USA flag logo/image

An Official Website of the United States Government

XRpro Discovery of Decorporation Agents

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93358
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AI079935
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Caldera Pharmaceuticals, Inc.
278 DP Road Suite D LOS ALAMOS, NM -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: XRpro Discovery of Decorporation Agents
Agency: HHS
Contract: 1R43AI079935-01A1
Award Amount: $600,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will use award-winning XRpro, a high throughput, label-free technology for producing nano-engineered radionuclide decorporation agents that are highly specific for their target radionuclide over similar elements. This proposal displays preliminary results showing specific decorporation agents for Sr(II) that do not bind Ca(II); Sr(II) is the only form of strontium (Sr) that is of concern for decorporation. Decorporation agents specific for element s such as Sr(II) and Co(II), which do not bind any essential metals, including Cu(II), Ca(II), Ni(II), Zn(II) are necessary. Emergency responders are currently forced to use non-selective chelators and blocking agents for radionuclide exposures. Sr-90 is e asily obtainable by terrorists who wish to do harm to US citizens, so Sr-90 decorporation is a very high national priority and treatments for Sr-90 exposures remain a critical need for the Strategic National Stockpile. Caldera's specific aims include using highly specific XRpro binding technologies to produce Sr decorporation agents. PUBLIC HEALTH RELEVANCE: Caldera Pharmaceuticals will use award-winning XRpro, a high throughput, label-free technology for producing nano-engineered radionuclide decorporation agents that are highly specific for their target radionuclide over similar elements. Emergency responders are currently forced to use non-selective chelators and blocking agents for radionuclide exposures. Sr-90 is easily obtainable by terrorists who wish to do harm to US citizens, so Sr-90 decorporation is a very high national priority and treatments for Sr-90 exposures remain a critical need for the Strategic National Stockpile.

Principal Investigator:

Benjamin P. Warner
5054122345
WARNER@CALDERA-PHARMACEUTICALS.COM

Business Contact:

Benjamin Warner
court@cpsci.com
Small Business Information at Submission:

CALDERA PHARMACEUTICALS, INC.
278 DP Road Suite D LOS ALAMOS, NM 87544

EIN/Tax ID: 200982060
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No